[NAVB] Navidea Biopharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 0.63 Change: 0.03 (4.8%)
Ext. hours: Change: 0 (0%)

chart NAVB

Refresh chart

Strongest Trends Summary For NAVB

NAVB is in the medium-term up 887% in 2 months. In the long-term down -76% below S&P in 11 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents. The company?s radiopharmaceutical development programs include Lymphoseek Injection, a receptor-targeted small-molecule radiopharmaceutical used in lymphatic mapping procedures, which are performed to evaluate breast cancer and melanoma; Manocept platform to target the CD206 mannose receptor expressed on macrophages; and NAV4694, an Fluorine-18 radiolabeled positron emission tomography imaging agent, which is used as an aid in the diagnosis of patients with signs or symptoms of cognitive impairment, such as Alzheimer?s disease. Its radiopharmaceutical development programs also comprise NAV5001, an Iodine-123 radiolabeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson?s disease and other movement disorders with potential use as a diagnostic aid in dementia; and NAV1800, a radiolabel

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 96.09% Sales Growth - Q/Q-4.09% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-286.47% ROE87.25% ROI925.9%
Current Ratio0.62 Quick Ratio0.58 Long Term Debt/Equity-6.01 Debt Ratio-0.36
Gross Margin75.86% Operating Margin-352.12% Net Profit Margin-409.87% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities3.5 M Cash From Investing Activities10 K Cash From Operating Activities-4.11 M Gross Profit2.54 M
Net Profit-9.69 M Operating Profit-6.25 M Total Assets22.2 M Total Current Assets19.53 M
Total Current Liabilities5.59 M Total Debt59.17 M Total Liabilities67.29 M Total Revenue2.87 M
Technical Data
High 52 week2.6 Low 52 week0.1 Last close1.43 Last change-4.03%
RSI22.53 Average true range0.27 Beta0.58 Volume455.46 K
Simple moving average 20 days-16.88% Simple moving average 50 days83.7% Simple moving average 200 days330.78%
Performance Data
Performance Week-30.58% Performance Month766.67% Performance Quart698.88% Performance Half587.5%
Performance Year508.51% Performance Year-to-date1292.41% Volatility daily62.61% Volatility weekly139.99%
Volatility monthly286.9% Volatility yearly993.85% Relative Volume192.99% Average Volume511.02 K
New High New Low

News

2019-06-18 16:05:00 | Navidea Biopharmaceuticals Announces Closing of Public Offering of Common Stock

2019-06-17 17:16:00 | Navidea Biopharmaceuticals Announces Day and Time of SNMMI Presentation of Phase 1/2 Study Results and Enrollment Update on its Phase 2B Study

2019-06-13 23:16:00 | Navidea Biopharmaceuticals Prices $6.0 Million Public Offering of Common Stock

2019-06-13 17:31:00 | Navidea Biopharmaceuticals Announces Proposed Public Offering of Common Stock

2019-06-13 16:24:00 | Navidea Biopharmaceuticals Regains Direct Control of Intellectual Property

2019-05-09 00:06:51 | Edited Transcript of NAVB earnings conference call or presentation 8-May-19 9:00pm GMT

2019-05-08 18:28:33 | Navidea: 1Q Earnings Snapshot

2019-05-08 16:05:00 | Navidea Biopharmaceuticals Reports First Quarter 2019 Financial Results

2019-05-01 16:05:00 | Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update

2019-04-26 07:30:00 | Navidea Biopharmaceuticals Announces Comparative Study to Evaluate the Potential Utility of Tilmanocept In Patients with Tuberculosis “TB”

2019-04-19 16:05:00 | Navidea Biopharmaceuticals Announces Reverse Stock Split

2019-04-08 07:30:00 | Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates

2019-04-02 16:05:00 | Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear Medicine and Molecular Imaging Annual Meeting

2019-03-22 17:08:00 | Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates

2019-03-08 00:15:55 | Edited Transcript of NAVB earnings conference call or presentation 7-Mar-19 10:00pm GMT

2019-03-07 16:05:00 | Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-28 07:00:00 | Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call and Business Update

2019-02-01 07:00:00 | Navidea Biopharmaceuticals Announces Extension of NYSE American Listing

2019-01-24 07:00:00 | Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court

2018-12-07 06:55:00 | Navidea Biopharmaceuticals Announces Patent Extension for Lymphoseek®

2018-11-29 16:35:00 | Navidea Biopharmaceuticals Appoints Adam Cutler to Board of Directors

2018-11-29 16:30:00 | Navidea Biopharmaceuticals Appoints Dr. Michael Rosol as Chief Medical Officer

2018-11-28 06:55:00 | Navidea Biopharmaceuticals to Present at the 11th Annual LD Micro Event 2018

2018-11-27 06:55:00 | Navidea Biopharmaceuticals Announces Presentation at the Radiological Society of North America RSNA 104th Scientific Assembly and Annual Meeting 2018

2018-11-26 16:30:00 | Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan to Board of Directors

2018-11-15 07:40:00 | Recent Analysis Shows Aquantia, Ubiquiti Networks, Reliv' International, Permian Basin Royalty Trust, Patriot Transportation Holding, and Navidea Biopharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

2018-11-08 01:21:25 | Edited Transcript of NAVB earnings conference call or presentation 7-Nov-18 9:30pm GMT

2018-11-07 18:45:46 | Navidea: 3Q Earnings Snapshot

2018-11-07 16:10:00 | Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Results

2018-11-01 07:00:00 | Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Conference Call and Business Update

2018-10-31 17:30:00 | Navidea Biopharmaceuticals Wins Dismissal of Platinum Litigation

2018-10-30 16:30:00 | Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American

2018-10-11 06:55:00 | Navidea Biopharmaceuticals to Present Data on the Manocept Platform at 2018 ACR Annual Meeting

2018-10-08 17:00:00 | Navidea Biopharmaceuticals to Present at the 2018 BIO Investor Forum

2018-09-18 08:44:46 | The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares

2018-09-17 17:30:00 | Navidea Biopharmaceuticals Announces Acceptance into the National Institutes of Health Commercialization Accelerator Program

2018-09-17 17:20:00 | Navidea Biopharmaceuticals Announces Closing of a $3 Million Private Placement

2018-08-16 21:40:33 | Edited Transcript of NAVB earnings conference call or presentation 16-Aug-18 9:00pm GMT

2018-08-16 15:00:00 | Navidea Biopharmaceuticals, Inc. to Host Earnings Call

2018-08-16 07:47:52 | What Does Navidea Biopharmaceuticals Inc’s NYSEMKT:NAVB Ownership Structure Look Like?

2018-08-16 07:00:00 | Navidea Biopharmaceuticals Announces Details of 2018 Annual General Meeting

2018-08-15 17:47:00 | Navidea Biopharmaceuticals Receives Noncompliance Notice From NYSE American

2018-08-08 19:05:42 | Navidea: 2Q Earnings Snapshot

2018-08-08 18:05:00 | Navidea Biopharmaceuticals Reports Second Quarter 2018 Financial Results

2018-07-12 17:47:00 | Navidea Management to Host Moderated Q&A Webcast to Provide Corporate Update

2018-06-14 17:37:00 | Navidea to Host Moderated Q&A Webcast with Management

2018-05-30 16:30:00 | Navidea Biopharmaceuticals to Present at 8th Annual LD Micro Invitational Conference and Participate in the 2018 BIO International Convention

2018-05-09 23:35:47 | Edited Transcript of NAVB earnings conference call or presentation 9-May-18 12:30pm GMT

2018-05-09 05:09:26 | Navidea: 1Q Earnings Snapshot

2018-05-08 17:00:00 | Navidea Biopharmaceuticals Reports First Quarter 2018 Financial Results